outcomes

Staging anorexia nervosa could improve outcomes, say experts

The current criteria for diagnosing anorexia nervosa fail to reflect clinical reality and should be changed to a staging model similar to that used to diagnose cancer or burns, says an Australian...

Outcomes that matter to patients

There’s no shortage of examples of clinicians and patients being misled by surrogate outcomes. In some cases the results have been catastrophic.

Show us the data: why clinical outcomes matter

Data from the NHS will have a key role in the British government’s plan for national economic recovery.

U.S Public Health Service Report Outlines Mechanisms to Optimize the Role of Pharmacists on the Healthcare Team

U.S Public Health Service Report Outlines Mechanisms to Optimize the Role of Pharmacists on the Healthcare Team   U.S. Surgeon General Supports Critical Concepts in Report   WASHINGTON, DC ...

Diffusion Tensor Imaging in Acute Optic Neuropathies: Predictor of Clinical Outcomes [Original Contribution]

Objective  To evaluate directional diffusivities within the optic nerve in a first event of acute optic neuritis to determine whether decreased axial diffusivity (AD) would predict 6-month visual outcome and optic nerve integrity measures.

Design  Cohort study.

Setting  Academic multiple sclerosis center.

Patients  Referred sample of 25 individuals who presented within 31 days after acute visual symptoms consistent with optic neuritis. Visits were scheduled at baseline, 2 weeks, and 1, 3, 6, and 12 months.

Effect of Aspirin on Vascular and Nonvascular Outcomes: Meta-analysis of Randomized Controlled Trials [Review Article]

Background  The net benefit of aspirin in prevention of CVD and nonvascular events remains unclear. Our objective was to assess the impact (and safety) of aspirin on vascular and nonvascular outcomes in primary prevention.

Data Sources  MEDLINE, Cochrane Library of Clinical Trials (up to June 2011) and unpublished trial data from investigators.

Study Selection  Nine randomized placebo-controlled trials with at least 1000 participants each, reporting on cardiovascular disease (CVD), nonvascular outcomes, or death were included.